Clinical study of tenofovir combined with silybin in the treatment of hepatitis B cirrhosis
Objective To analyze the clinical effect of tenofovir combined with silybin in the treatment of hepatitis B cirrhosis.Methods 86 patients with hepatitis B cirrhosis were divided into group A(43 cases)and group B(43 cases)according to different medication regimens.Group A was treated with tenofovir,and group B was treated with tenofovir and silybin.Comparison was made on liver function indicators[alanine aminotrasferase(ALT),aspartate transaminase(AST),total bilirubin(TBIL)],liver fibrosis indicators[type Ⅳcollagen(CⅣ),amino-terminal peptide of type Ⅲ procollagen(PⅢNP),laminin(LN),hyaluronic acid(HA)],Child-Pugh score,clinical efficacy,and occurrence of adverse reactions between the two groups.Results After medication,ALT,AST and TBIL of group B were(36.57±6.57)U/L,(30.93±4.87)U/L and(20.66±2.30)μmol/L,which were lower than(50.12±7.20)U/L,(42.76±5.53)U/L and(29.83±2.89)μmol/L in group A(P<0.05).After medication,CⅣ,PⅢNP,LN and HA in group B were(65.77±20.53),(115.93±34.51),(85.61±24.28)and(104.93±32.15)μg/L,which were lower than(92.52±27.28),(143.76±45.40),(107.54±32.73)and(152.34±41.72)μg/L in group A(P<0.05).The Child-Pugh score of group A was(8.66±1.54)points before medication,and(6.92±1.36)points after medication.The Child-Pugh score of group B was(8.70±1.51)points before medication,and(5.73±1.10)points after medication.Before medication,there was no difference in Child-Pugh scores between the two groups(P>0.05).After medication,the Child-Pugh score of group B was lower than that of group A(P<0.05).The total effective rate was 79.07%(34/43)in group A and 95.35%(41/43)in group B.The total effective rate of group B was higher than that of group A(P<0.05).The total incidence of adverse reactions was similar between the two groups(P>0.05).Conclusion Tenofovir combined with silybin has a good effect in the treatment of hepatitis B cirrhosis,which can significantly improve the liver function indicators and liver fibrosis indicators of patients,contribute to the good control of patients'disease,and the total effective rate is high.It does not increase the adverse reactions compared with the use of tenofovir treatment alone,the effectiveness and safety of both are better,and can be adopted and implemented.
TenofovirSilybinHepatitis B cirrhosisLiver functionLiver fibrosisChild-Pugh score
万方数据
维普
